Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for New Horizon Health's EV-to-EBIT or its related term are showing as below:
FRA:6YZ's EV-to-EBIT is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.4 * Ranked among companies with meaningful EV-to-EBIT only.
New Horizon Health (FRA:6YZ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
New Horizon Health's Enterprise Value for the quarter that ended in Jun. 2023 was €1,278.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €0.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health EV-to-EBIT Related Terms
New Horizon Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for New Horizon Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, New Horizon Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where New Horizon Health's EV-to-EBIT falls into.
New Horizon Health's current Enterprise Value is €702.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €0.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (FRA:6YZ) has a EV-to-EBIT of 830.75 as of Sep. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's EV-to-EBIT too high?
New Horizon Health's current EV-to-EBIT is 830.75. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. New Horizon Health's value of 830.75 is 4414.9% above this industry median. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's EV-to-EBIT compare to ABT and SYK?
New Horizon Health's EV-to-EBIT of 830.75 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBIT is 18.40. New Horizon Health's value of 830.75 is 4414.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Horizon Health's current EV-to-EBIT of 830.75 is 4414.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on New Horizon Health and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Horizon Health's current EV-to-EBIT is 830.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current EV-to-EBIT of 830.75. The current EV-to-EBIT is 830.75 and 4414.9% above the Medical Devices & Instruments industry median of 18.40. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current EV-to-EBIT is 830.75 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score
Get the complete analysis for FRA:6YZ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YZ has been successfully added to your 
